Avinger Stock Forecast, Price & News

-0.02 (-2.00 %)
(As of 08/4/2021 02:41 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume8,776 shs
Average Volume1.03 million shs
Market Capitalization$88.15 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVGR News and Ratings via Email

Sign-up to receive the latest news and ratings for Avinger and its competitors with MarketBeat's FREE daily newsletter.

Avinger logo

About Avinger

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.76 out of 5 stars

Medical Sector

798th out of 1,309 stocks

Surgical & Medical Instruments Industry

83rd out of 121 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Avinger (NASDAQ:AVGR) Frequently Asked Questions

Is Avinger a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Avinger stock.
View analyst ratings for Avinger
or view top-rated stocks.

What stocks does MarketBeat like better than Avinger?

Wall Street analysts have given Avinger a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avinger wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avinger's next earnings date?

Avinger is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Avinger

How can I listen to Avinger's earnings call?

Avinger will be holding an earnings conference call on Tuesday, August 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Avinger's earnings last quarter?

Avinger, Inc. (NASDAQ:AVGR) announced its quarterly earnings results on Thursday, May, 6th. The medical device company reported ($0.07) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.01. The medical device company earned $2.56 million during the quarter. Avinger had a negative trailing twelve-month return on equity of 131.09% and a negative net margin of 200.98%.
View Avinger's earnings history

How has Avinger's stock price been impacted by COVID-19 (Coronavirus)?

Avinger's stock was trading at $0.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVGR stock has increased by 115.0% and is now trading at $0.9245.
View which stocks have been most impacted by COVID-19

When did Avinger's stock split? How did Avinger's stock split work?

Shares of Avinger reverse split on Wednesday, January 31st 2018. The 1-40 reverse split was announced on Tuesday, January 30th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 30th 2018. An investor that had 100 shares of Avinger stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for AVGR?

2 equities research analysts have issued 12-month price targets for Avinger's stock. Their forecasts range from $2.50 to $2.50. On average, they anticipate Avinger's share price to reach $2.50 in the next year. This suggests a possible upside of 170.4% from the stock's current price.
View analysts' price targets for Avinger
or view top-rated stocks among Wall Street analysts.

Who are Avinger's key executives?

Avinger's management team includes the following people:
  • Mr. Jeffrey M. Soinski, Pres, CEO & Director (Age 59, Pay $504.9k)
  • Mr. Mark B. Weinswig, Chief Financial Officer (Age 48, Pay $359.44k)
  • Mr. Himanshu N. Patel, Chief Technology Officer (Age 61, Pay $359.44k)
  • Mr. Keith Schaefer, Chief Operating Officer

Who are some of Avinger's key competitors?

What other stocks do shareholders of Avinger own?

When did Avinger IPO?

(AVGR) raised $60 million in an IPO on Friday, January 30th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

What is Avinger's stock symbol?

Avinger trades on the NASDAQ under the ticker symbol "AVGR."

How do I buy shares of Avinger?

Shares of AVGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avinger's stock price today?

One share of AVGR stock can currently be purchased for approximately $0.92.

How much money does Avinger make?

Avinger has a market capitalization of $88.15 million and generates $8.76 million in revenue each year. The medical device company earns $-19,010,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does Avinger have?

Avinger employs 69 workers across the globe.

What is Avinger's official website?

The official website for Avinger is

Where are Avinger's headquarters?

Avinger is headquartered at 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063.

How can I contact Avinger?

Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The medical device company can be reached via phone at 650-241-7900 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.